Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral breast cancer~* Large operable breast cancer/LOBC (T3N0M0 or T3N1M0) and Locally advanced breast cancer/LABC (T3N1-2M0; T2N2M0)~* Age \<70 years~* Fit for CT~Exclusion Criteria:~* Prior IB or EB~* Metastatic breast cancer~* Renal failure or deranged RFT~* Hypoparathyroidism~* Pregnant or lactating mothers or women of childbearing age not practicing contraception~* Patient on any of the following drugs: Magnesium-containing antacids, Digitalis, Phenytoin barbiturates, Thiazide diuretics.~* Previous history of other cancers except cured skin and cervical carcinoma in situ.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- No additional treatment (Type: NO_INTERVENTION): No Injection Vit D3 or Injection Progesterone prior to chemotherapy cycle
- Inj. Proluton (Type: ACTIVE_COMPARATOR): Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
- Inj. Arachitol (Type: ACTIVE_COMPARATOR): Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
- Inj. Proluton and Inj. Arachitol (Type: ACTIVE_COMPARATOR): Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM and Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).